Heterocyclic Compounds Block PD-1/PD-L1 Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively block the PD-1/PD-L1 protein interaction, which is crucial for augmenting T cell responses in diseases like cancer, as cancer cells often evade immune suppression by upregulating PD-L1 expression.
Innovation Solution
Development of compounds that modulate PD-1/PD-L1 protein interactions, specifically represented by Formula (I) compounds or their pharmaceutically acceptable salts and stereoisomers, which can be administered to inhibit PD-1/PD-L1 interaction, thereby enhancing immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cancer cells upregulate PD-L1 expression to evade immune suppression, then the immune system's ability to control cancer is reduced, but the PD-1/PD-L1 interaction becomes more prominent as a therapeutic target
Solution Approach 1:
The patent employs small molecule compounds as intermediaries to block the PD-1/PD-L1 protein-protein interaction. These compounds act as mediators that prevent the binding between PD-1 receptor on T cells and PD-L1 ligand on cancer cells, thereby restoring immune surveillance without requiring direct modification of the immune system or cancer cells
Solution Approach 2:
The invention changes the binding parameters of the PD-1/PD-L1 interaction by introducing compounds that alter the affinity and specificity of the protein-protein binding. By modifying the interaction parameters through competitive binding, the therapeutic effect is achieved while maintaining the natural immune system architecture
2Reliability
If blocking PD-1/PD-L1 interaction is used to enhance T cell responses, then therapeutic effectiveness against cancer is improved, but the complexity of drug development increases
Solution Approach 1:
The patent replaces complex biologics (such as monoclonal antibodies) with smaller small molecule compounds that can orally bioavail and achieve the same therapeutic effect of blocking PD-1/PD-L1 interaction. This substitution simplifies the drug development process, reduces manufacturing complexity, and improves patient compliance while maintaining therapeutic effectiveness
3Adaptability or versatility
If current therapies are used to treat cancer, then treatment options are limited, but the ability to effectively block PD-1/PD-L1 interaction is insufficient
Solution Approach 1:
The patent employs structure-activity relationship (SAR) optimization to systematically modify compound parameters including molecular weight, lipophilicity, hydrogen bond donors/acceptors, and binding affinity. By changing these physicochemical parameters, the invention achieves both effective PD-1/PD-L1 blocking capability and desirable pharmacological properties for clinical translation
Solution Approach 2:
The invention utilizes composite molecular structures combining heterocyclic cores with various functional groups and substituents to achieve both target binding affinity and optimal drug-like properties. These composite structures integrate multiple pharmacophoric elements into single molecules that can effectively block PD-1/PD-L1 interaction while maintaining良好的 pharmacokinetics
Data Source
AI summary
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.